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Abstract Patients with chronic daily headache (CDH) are difficult to treat. A combination of general measures and specific pharmacological treatments is necessary. When possible, pharmacological management should be planned on an outpatient basis. The general protocol should include abrupt discontinuation of the offending symptomatic medications, specific treatment for detoxification, daily nonsteroidal anti-inflammatory drugs (NSAIDs) for about 1 month, triptans only for moderate-severe headache, and prophylactic treatment. Either amitriptyline plus propranolol or valproic acid have been classically recommended for transformed migraine prophylaxis. Refractory patients can respond to a combination of a beta-blocker and valproic acid, possibly due to their complementary mechanisms of action. Recently, the new antiepileptic topiramate has been shown to be especially useful in this indication. At least one-third of patients, however, do not improve. Therefore, the best treatment of this incapacitating entity continues to be its prevention. Preventive measures should include: (1) public information concerning the risk of frequent self-treatment for headaches; (2) inform headache patients of the risk of analgesic overuse/rebound headache; (3) recommend NSAIDs and triptans as symptomatic medications; and (4) active use of preventive medications when headaches begin to increase in frequency.
patients suffer from TM, 20% from CTTH and 20% meet NDPH criteria. Most, some 80%, overuse symptomatic medications. Our data taken from a big (almost 5,000 subjects) sample of the general population indicate that 1.4% meet diagnostic criteria for CDH with analgesic overuse [3, 4] .
Therefore, CDH is a very frequent reason for consultation in headache clinics, which reflects its prevalence of almost 5% in the general population, the proportion of CTTH and TM cases being quite similar. From epidemiological data it can be concluded that analgesic overuse is not the cause of CDH in most patients, even though analgesic overuse is both a precipitating and an aggravating factor for CDH in patients with primary headache prone to this phenomenon [3, 4] .
In a clinic-based study of 630 patients with CDH, including patients with TM, CTTH and NDPH, the Minnesota Multiphasic Personality Inventory was abnormal in 61% of subjects compared with 12.2% of patients with episodic migraine. In several subspecialty centerbased studies, depression occurred in about 80% of TM subjects. Psychiatric comorbidity is a predictor of headache intractability. The Minnesota Multiphasic Personality Inventory was abnormal in 100% of patients with CDH who failed to respond to aggressive management, compared with 48% of the responders [5] .
In the general population, one-third of CDH subjects meet depression criteria, and almost two-thirds show personality abnormalities, either neuroticism, psychoticism or both. Personality abnormalities are more frequent in abusers (82%) than in non-abusers (55%) [6] .
Pathophysiology
Although the pathophysiology of CDH is unknown, recent work suggests that several mechanisms could contribute to the process. CDH may be due to: (1) abnormal excitation of peripheral nociceptive afferent fibers, perhaps due to chronic neurogenic inflammation; (2) enhanced responsiveness of the nucleus caudalis neurons, i.e., central sensitization; (3) decreased pain modulation; (4) spontaneous central pain; or (5) a combination of these. These mechanisms need an individual genetic predisposition to develop into CDH.
Treatment
Patients suffering from CDH are difficult to treat. A combination of general measures and specific pharmacological treatments is necessary. General measures include: (1) promoting good communication between patient and physician; (2) reassurance, excluding secondary headaches; (3) identifying comorbid medical/psychiatric conditions; (4) recognizing the subtype of CDH; and (5) concomitant behavioral intervention.
When possible, pharmacological management should be planned on an outpatient basis ( Table 1 ). The general protocol should include: (1) abrupt discontinuation of the offending symptomatic medications (if there is overuse); (2) specific treatment for detoxification; (3) daily nonsteroidal antiinflammatory drugs (NSAIDs) for about 1 month; (4) triptans only for moderate-severe headache; and (5) preventive treatment. We recommend low doses of amitriptyline (10-25 mg daily) for CTTH patients, valproic acid (around 500 mg daily) usually being the second option if amitriptyline fails. For TM patients, either amitriptyline plus propranolol or valproic acid have been classically recommended. Refractory patients can respond to a combination of a beta-blocker and valproic acid, possibly due to their complementary mechanisms of action [6] (Fig. 1) . Recently, the new antiepileptic topiramate (ideal dose around 100 mg daily) has been shown to be especially useful in at least 50% of CDH patients, even in those refractory to the above-mentioned therapies. About 15-20% of patients experience cognitive adverse events with this drug, which completely disappear once the drug is stopped. Three advantages of topiramate in this indication are: (1) there is no need for blood tests, (2) efficacy appears earlier than with the other drugs, and (3) it is the only drug that does not lead to weight gain, in fact patients taking topiramate usually lose between 1 and 5 kg [7] (Fig. 2) . The potential value of other emerging drugs, such as botulinum toxin type A, remains to be shown in placebo-controlled studies.
Inpatient management is indicated when the outpatient protocol has failed, in the presence of high depression scores, or if the patient takes significant doses of tranquilizers, codeine, or barbiturates. The specific protocol for these complicated patients in our center usually includes: (1) i.v. dihydroergotamine (+metoclopramide) 0.5-1 mg/8 h for 3-8 days; (2) i.v. methylprednisolone 80 mg/24 h, for 3 days; (3) i.v. valproate 400 mg/12 h, for 3-4 days, then oral prophylaxis with 500-1,000 mg daily; (4) short treatment with benzodiazepines (1-2 weeks); and (5) NSAIDs and triptans as mentioned above.
Prognosis
The natural history of CDH has not been studied in detail.
After the treatments we have already commented on, around 60% of patients improve significantly in long-term follow-up and their chronic headache is transformed into an intermittent one. At least one-third, however, do not improve. Therefore, the best treatment of this incapacitating entity continues to be its prevention. Preventive measures should include: (1) public information concerning the risk of frequent self-treatment for headaches; (2) inform headache patients of the risk of analgesic overuse/rebound headache; (3) recommend NSAIDs and triptans as symptomatic medications; and (4) active use of preventive medications when headaches begin to increase in frequency. 
